Accueil   Diary - News   All news Valneva and Emergent BioSolutions Join Forces to Develop a Vaccine against the Zika Virus

Valneva and Emergent BioSolutions Join Forces to Develop a Vaccine against the Zika Virus

Lyon (France), July 26, 2017 - Valneva SE (VLA), a fully integrated, commercial stage biotech company focused on developing innovative, life-saving vaccines, announces today that it has granted Emergent BioSolutions Inc. (NYSE:EBS) exclusive worldwide rights to its Zika vaccine technology ZIKV. Valneva and Emergent will co-develop ZIKV-VLA1601, a highly purified inactivated vaccine candidate against the Zika virus, which was successfully developed by Valneva using the established inactivated manufacturing platform of its licensed Japanese Encephalitis vaccine IXIARO® / JESPECT® .

 

Emergent and Valneva seek to initiate a Phase I clinical trial in the U.S. in late 2017 or early 2018 and anticipate Phase I data within six months after trial initiation.

Read the press release